CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Denosumab (Drug Plan Submission)

Last Updated: October 2, 2015
Result type: Reports
Project Number: SR0433-001
Product Line: Reimbursement Review

Generic Name: Denosumab (Drug Plan Submission)

Brand Name: Xgeva

Manufacturer: Amgen Canada Inc.

Indications: Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer

Submission Type: Drug Plan Initiated

Project Status: Complete

Date Recommendation Issued: March 23, 2016

Recommendation Type: List with clinical criteria and/or conditions